FDA Approval Application for Linagliptin by Teva Pharmaceuticals
Teva Pharmaceuticals has submitted an original application for Linagliptin under ANDA208433 with a standard review priority.
Company
Teva
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
Teva Pharmaceuticals' submission for Linagliptin under ANDA208433 represents a significant competitive move in the diabetes market. This could disrupt pricing and market share dynamics for existing DPP-4 inhibitors, necessitating strategic adjustments from incumbents.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the FDA's review timeline and any subsequent approval announcements for Linagliptin.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.